Mealeys

Recent Posts

New Trial Sought After $113M Verdict In Attempted Monopolization Case
Posted on 16 Oct 2013 by Mealeys

MARSHALL, Texas - Becton, Dickinson & Co. (BD) on Oct. 11 moved for judgment as a matter of law or, alternatively, a new trial following a federal jury in Texas' $133,508,014 damage award in favor of Retractable Technologies Inc.(RTI) on its claim... Read More

Drug Companies Tell High Court That Reverse-Payment Settlements Are Lawful
Posted on 26 Feb 2013 by Mealeys

WASHINGTON, D.C. - Several drug companies told the U.S. Supreme Court in their merits briefs on Feb. 21 that the court should analyze antitrust challenges to reverse-payment settlements of patent litigation between the holder of a drug patent and potential... Read More

Sham Litigation Claims Against Biovail Are Settled; Case Against GSK Continues
Posted on 25 Jul 2012 by Mealeys

PHILADELPHIA - Biovail Corp., the manufacturer of the prescription antidepressant drug Wellbutrin XL, reached a $37.5 million settlement on July 23 with direct purchasers who claimed that Biovail illegally conspired to prevent generic versions of the... Read More

$150M Settlement Receives Final Approval In Flonase Sham Litigation Case
Posted on 18 Jun 2013 by Mealeys

PHILADELPHIA - A federal judge in Pennsylvania on June 14 granted final approval to a $150 million cash settlement between Flonase manufacturer GlaxoSmithKline PLC (GSK) and a certified class of 33 direct purchasers on the direct purchasers' claims... Read More

Nexium Direct Purchasers Granted Class Certification In Pay-For-Delay Suit
Posted on 13 Dec 2013 by Mealeys

BOSTON - A federal judge in Massachusetts on Dec. 11 certified a nationwide class of direct purchasers of Nexium on their antitrust claims contending that the manufacturer of the heartburn medication and generic drug manufacturers entered into reverse... Read More

3rd Circuit Will Not Stay Mandate In Reverse-Payment Settlements Case
Posted on 22 Aug 2012 by Mealeys

PHILADELPHIA - The Third Circuit U.S. Court of Appeals on Aug. 17 denied drug makers' motion to stay the mandate pending the filing of a petition for a writ of certiorari in the U.S. Supreme Court in a case in which the appeals court ruled that settlements... Read More

GlaxoSmithKline, Third-Party Payers' Antitrust Settlement Is Approved
Posted on 17 Jan 2013 by Mealeys

PHILADELPHIA - A federal judge in Pennsylvania on Jan. 14 granted preliminary approval to a $21.5 million cash settlement on third-party payers' (TPP) class claims that GlaxoSmithKline PLC (GSK) engaged in a fraudulent scheme to extend patent protection... Read More

Calif. Cipro Purchasers Seek Approval Of Settlement With Bayer Over Pay-For-Delay
Posted on 15 Jul 2013 by Mealeys

SAN DIEGO - California purchasers of the antibiotic Cipro and third-party payers who reimbursed for California purchases of Cipro on July 11 asked a state court to grant preliminary approval to their $74 million cash settlement with Bayer Corp. and Bayer... Read More

3rd Circuit: Reverse-Payment Settlements Are Subject To Rule-Of-Reason Analysis
Posted on 17 Jul 2012 by Mealeys

PHILADELPHIA - Settlements involving a reverse payment from a name-brand manufacturer to a generic challenger to delay the entry date for marketing a generic drug are subject to the rule-of-reason test and not the scope-of-the-patent test, the Third Circuit... Read More

California Cipro Purchasers' Settlement With Bayer Over Pay-For-Delay Is Approved
Posted on 19 Nov 2013 by Mealeys

SAN DIEGO - A judge in California on Nov. 15 granted final approval to a $74 million cash settlement between Bayer Corp. and Bayer AG (collectively, Bayer) and California purchasers of the antibiotic Cipro and third-party payers who reimbursed for California... Read More

11th Circuit Will Not Reconsider Upholding Reverse Payment Settlements
Posted on 20 Jul 2012 by Mealeys

ATLANTA - The 11th Circuit U.S. Court of Appeals on July 18 denied the Federal Trade Commission's petition for rehearing en banc of the court's April 25 ruling that reverse payment settlements between the holder of a drug patent and generic manufacturers... Read More

Reverse-Payment Settlement Case Remanded In Light Of Supreme Court Ruling
Posted on 10 Sep 2013 by Mealeys

ATLANTA - Following the U.S. Supreme Court's ruling in June that reverse-payment settlements of patent litigation between the holder of a drug patent and potential generic manufacturers of the drug are subject to the rule of reason, the 11th Circuit... Read More

Federal Judge Dismisses Sham Patent Litigation Claims In AndroGel Antitrust Case
Posted on 3 Oct 2012 by Mealeys

ATLANTA - The federal judge in Georgia overseeing the multidistrict litigation in which direct and indirect purchasers allege that reverse settlement payments involving AndroGel violated antitrust laws ruled Sept. 28 that the brand-name drug company's... Read More

Jury Awards $113M For Attempted Monopolization Of Safety Syringe Market
Posted on 23 Sep 2013 by Mealeys

MARSHALL, Texas - A federal jury in Texas on Sept. 19 awarded Retractable Technologies Inc.(RTI) $133,508,014 in damages against Becton, Dickinson & Co. (BD) for attempted monopolization of the market for safety syringes through deceptive practices... Read More

Reverse-Payment Settlements Are Presumptively Anti-Competitive, FTC Argues
Posted on 24 Jan 2013 by Mealeys

WASHINGTON, D.C. - The Federal Trade Commission told the U.S. Supreme Court in its opening merits brief on Jan. 22 that reverse-payment settlements of patent litigation between the holder of a drug patent and potential generic manufacturers of the drug... Read More